Skip to main content
. 2017 Apr 3;36(32):4641–4652. doi: 10.1038/onc.2017.91

Figure 2.

Figure 2

GLI1 inhibition diminishes proliferation and stemness in LAC cells. (ad) LAC cells viability is diminished by GLI1 knockdown in (a) commercial cell lines (siRNA-mediated) and (b) patient-derived CSCs (shRNA-mediated); similar reductions are seen in (c) cell lines and (d) CSCs treated for 48 h with the GLI1 antagonist GANT61 or DMSO (−). Bar graphs show viability (MTS assay); immunoblots show endogenous GLI1 protein levels. LC: GAPDH. Numbers below blots indicate densitometrically quantified protein expression. (e) Effects of GANT61 on oncosphere formation in LAC CSC lines before and after transduction with shGLI1. Bar graphs: frequencies of oncosphere-forming cells (OFC, % of seeded cells that formed oncospheres) under indicated experimental conditions are normalized to the frequency observed in shSCRAMBLE-infected cells treated with DMSO alone (controls, CTRL, expressed as 100%). Photomicrographs: Representative images of oncospheres observed in DMSO-treated CSCs infected with shGLI1 or shSCRAMBLE (CTRL). Scale bar: 50 μm. (f) Percentage of CSCs exhibiting high ALDH activity (ALDH+ cells) after GANT61 or CTRL treatment (AldeFluor assay). (g) Expression (mRNA and protein) of stem cell markers OCT4 and ABCG2 in GANT61- and CTRL-treated (dashed line) CSCs. LC: GAPDH. *P< 0.05. ALDH, aldehyde dehydrogenase.